Variant
ESR2 beta-2 and beta-5
CI-VAR-00004878Explore in graph →CIViC 3477
Curated evidence
Evidence by cancer (2 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 15591034
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Breast Neoplasm1 | ||||||||
| ESR2 beta-2 and beta-5 | (prognostic) | Prognostic | B | Supports Better Outcome | 4 | submitted | EID9611In a clinical trial including 105 patients, beta-2 expression is significantly associated with an increased RFS (p = 0.006) and OS (p= 0.0008) by a multivariate analysis. This significative correlatio… (full text at CIViC) PMID 15591034 · Davies et al., 2004 · Open in CIViC | civic |
| Malignant Prostate Neoplasm1 | ||||||||
| ESR2 beta-2 and beta-5 | (prognostic) | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID9617In a clinical study including 144 patients, nuclear beta-2 expression is significantly correlated with decreased RFS (p < 0.01), decreased MFS (p < 0.01) and PSA failure (p < 0.01). Moreover cytoplasm… (full text at CIViC) PMID 20501637 · | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available